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Background: The role of the gut microbiome in arresting pathogen colonization and growth is important for
protection against Clostridium difficile infection (CDI). Observational studies associate proton pump inhibitor (PPI)
use and CDI incidence. We hypothesized that PPI use affected the distal gut microbiome over time, an effect that
would be best explored by time-longitudinal study of healthy subjects on PPI in comparison to treatment-naïve CDI
subjects. This study enrolled nine healthy human subjects and five subjects with treatment-naïve CDI. After random
assignment to a low (20 mg/day) or high (2× 20 mg/day) dose group, fecal samples were collected from the nine
healthy subjects before, during, and after 28 days of PPI use. This was done in conjunction with pre-treatment fecal
collection from CDI subjects. High-throughput sequencing (16S rRNA) was performed on time-longitudinal samples
to assess changes to the healthy gut microbiome associated with prolonged PPI usage. The healthy samples were
then compared to the CDI subjects to explore changes over time to the gut microbiome associated with PPI use
and potentially related to CDI.
Results: We report that PPI usage at low and high dosages, administered for 28 days, resulted in decreases to
observed operational taxonomic unit (OTU) counts after both 1 week and 1 month. This decrease resulted in
observed OTU levels that were similar to those found in treatment-naïve CDI patients, which was partly reversible
after a 1 month recovery period. We did not detect a dose-dependent difference in OTU levels nor did we detect
significant changes in taxa previously reported to be affected by PPI treatment.
Conclusion: While our observation of diminishing observed OTU counts during PPI therapy is a preliminary finding
in a small cohort, our hypothesis that PPIs disrupt the healthy human gut microbiome is supported in this group.
We conclude that decreases in observed species counts were reversible after cessation of PPI usage within
1 month. This finding may be a potential explanation for the association between prolonged PPI usage and CDI
incidence.
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Proton pump inhibitors (PPIs) are potent inhibitors of gas-
tric acid production that are highly effective for treating
acid-mediated disorders of the upper digestive tract [1].
PPIs are one of the most commonly prescribed medica-
tions in the USA, with billions of dollars in annual sales
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unless otherwise stated.[3], epidemiological studies have linked PPIs to several nu-
tritional, metabolic, and infectious disorders. Specifically,
their prolonged use has been associated with iron [4]
and vitamin B12 [5,6] deficiencies, hypomagnesemia
[7], osteoporosis-related fractures [8,9], small intestinal
bacterial overgrowth [10,11], and community-acquired
pneumonia [12,13]. Furthermore, several recent studies
have found an association between the use of PPIs and the
development of Clostridium difficile infection (CDI) [14-18].
A meta-analysis of 39 studies reported a 1.74-fold increase
in risk of CDI in PPI users (95% confidence interval 1.47-
2-05) [19]. This association with the most commond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Administration (FDA) to require that the package insert
for PPIs contain a warning that PPIs may increase the risk
of CDI [20].
Despite this epidemiological association, the reason why
PPIs might increase CDI risk is not known. Although
hypochlorhydria increases susceptibility to enteric bacterial
infections, C. difficile spores are unaffected by gastric acid-
ity [21]. The intestinal microbiota play an important func-
tion in suppressing pathogen growth (i.e., colonization
resistance) [22], and alterations in the microbiota by PPIs
may induce C. difficile proliferation. The loss of colonic mi-
crobial diversity is a characteristic feature of CDI [23,24].
Microbiome analysis of the feces has been shown to
improve the ability to distinguish CDI status when com-
paring cases with both diarrheal and non-diarrheal controls
[25]. Prolonged use of PPIs has been linked to changes in
the microbial community composition of the upper intes-
tinal tract in vitro [10,11,26,27]. Gastric acid reduction may
also influence the microbial composition of the lower
gastrointestinal (GI) tract [26]. The longitudinal changes in
the gut microbial ecology during and after PPI use and
how these relate to the microbiota present in CDI remain
unknown.
The purpose of this study was to investigate the impact
of short- and long-term PPI use on the fecal microbiota
and to compare these changes to persons with newly diag-
nosed CDI. If similar, it would provide a potential mech-
anism for the association of PPIs with an increased risk of
CDI. Changes to the fecal microbial community induced
by PPI use were assessed in healthy humans using high-
throughput 16S hypervariable tag sequencing and com-
pared to patients with a treatment-naïve first episode of
CDI. Our results demonstrate that microbial diversity
declines following prolonged (28-day) PPI usage. This
decrease results in observed operational taxonomic unit
(OTU) levels that are similar to those found in treatment-
naïve CDI patients. The reduction in observed OTU levels
was not always reversible 1 month after ceasing treatment.
Results
Study participants
Ten healthy volunteers (five women, five men) were ran-
domly assigned to receive omeprazole 20 mg once daily
(n =5) or twice daily (n =5) for 28 days. Volunteers
ranged in age from 18 to 57 years (mean ± standard de-
viation: 40.8 ± 15.3 years), with body mass indices (BMI)
ranging from 18.6 to 29.7 kg/m2 (mean ± standard devi-
ation: 24.8 ± 3.7 kg/m2). Stool samples were collected
prior to baseline (T0) and following 7 days (T7) and
28 days (T28) of omeprazole use. A final stool sample
was collected 1 month after discontinuation of omepra-
zole (T56). Fecal DNA was sequenced and compared to
that from five treatment-naïve CDI patients, all women,ranging in age from 20 to 63 years (mean ± standard devi-
ation: 40.8 ± 15.9 years) with BMI ranging from 16.6 to
39.4 kg/m2 (mean ± standard deviation: 28.1 ± 8.7 kg/m2).
No adverse events were reported amongst the healthy
subjects receiving omeprazole. One healthy subject was
withdrawn from the study after providing the baseline and
the first on-PPI stool samples due to subsequent antibiotic
use prescribed by his primary care provider.
The OTUs corresponding to Clostridium in CDI sub-
jects were assessed to determine if C. difficile could be
detected across all five subjects. C. difficile BI1 was de-
tected in 4/5 CDI subjects (as OTU 57). Other major
Clostridium associated with CDI subjects included Clos-
tridium butyricum (as OTU 377) in 4/5 CDI subjects and
Clostridium perfringens (as OTU 393) in 3/5 CDI subjects.
Sequencing
The total number of utilized read-pairs per sample from
healthy volunteers and CDI patients was 14,635,736
(mean ± standard deviation 340,366 ± 500,176). The lowest
read-count of a sample was 75,506 (see Additional file 1:
Metadata). Rarefaction plots measuring observed-OTU di-
versity indicate that all samples were sequenced past expo-
nential species accumulation (Additional file 2: Figure S1).
PPI use is associated with reduced OTU diversity
After rarefaction of all samples to 75,000 reads, a significant
difference in observed OTU count between baseline and
1 month was observed (Figure 1, Table 1). To determine the
robustness of this observed difference to sampling depth,
sensitivity analysis was performed by generating additional
rarefactions of 50,000 and 25,000 reads/sample to assess the
effect of reduced read depth (Additional file 2: Figure S2).
The significant change in observed species count between
baseline and 1 month on PPI remained significant at 50,000
and 25,000 reads/sample (Additional file 2: Table S1).
Microbial diversity differences between genders in PPI
users
After dividing subjects by gender and comparing observed
OTU counts across all time points, a statistically significant
difference between observed OTU counts in men (n =4)
and women (n =5) on PPIs was found (p ≈ 0.004, Additional
file 2: Figure S3). However, when observed OTU counts at
each time point (T0, T7, T28, T56) for men and women
were compared, the differences observed were not signifi-
cant (p≈ 0.10, p ≈ 0.21, p ≈ 0.10, p≈ 0.10). For observed
OTU counts, the mean ± standard deviation for women was
226 ± 55 and 293 ± 77 for men.
No PPI dose-dependent effect on diversity
A comparison of OTU counts between the high (twice
daily PPI) and low (once daily PPI) dose groups revealed


















Figure 1 Observed OTU counts on proton pump inhibitors. Plot depicts patient observed-OTU counts at start of treatment, 1 week into
treatment, and at the end of the 1-month program, followed by final collection 1 month after ceasing PPI usage. Five first-incidence C. difficile
patients had stool isolated and sequenced to represent the C. difficile cohort. Black horizontal bars represent within-group means. All statistical
tests using matched-pair healthy volunteers used Wilcoxon signed rank; statistical tests between healthy volunteer groups (*p <0.05, **p <0.005) and C.
difficile group used Wilcoxon rank sum (§p <0.05, §§p <0.01).
Seto et al. Microbiome 2014, 2:42 Page 3 of 11
http://www.microbiomejournal.com/content/2/1/42prior to omeprazole use) between the groups at baseline,
7 days on PPI, 28 days on PPI, or 1 month after stopping
the PPI (p ≈ 0.2778, p ≈ 0.2063, p ≈ 0.5556, p ≈ 0.2778,
respectively). After separating subject time points into
two groups based on dosage, no significant difference
was detected between the 20-mg once/day and 20-mg
twice/day groups (p ≈ 0.072); mean ± standard devi-
ation for the once daily omeprazole group was 239 ±Table 1 Statistical significance of observed OTU changes
between sample groups




T56 0.0328 0.9102 0.1069
CDa 0.0051 0.0112 0.0829 0.0599
Table of statistical tests between matched-pair healthy subject time intervals
to determine the significance of measured differences in observed species
counts. Species counts were calculated from samples rarefied to 75,000 reads.
Testing for matched-pair healthy samples used one-tailed (alternative = “greater”)
Wilcoxon signed rank.
aNon-matched pair probabilities for groups with C. difficile (CD) were
calculated using one-tailed (alternative = “greater”) Wilcoxon rank sum with
continuity correction.62 and for the twice daily omeprazole group was 277 ±
81 (Additional file 2: Figure S4).
Longitudinal gut microbe composition is largely stable
After rarefaction of all samples to 75,000 reads, the per-
cent of OTUs that remained throughout the course of the
PPI therapy varied between 14.33% and 37.38% (median ±
MAD of 25.3% ±9.5%) across the nine subjects, corre-
sponding to longitudinal trend 1111 (Additional file 2:
Table S2). Of the total OTUs observed in the subjects,
4.08%–14.13% (Median ±MAD of 7.7% ±1.6%) appeared
after the conclusion of the PPI therapy, corresponding to
longitudinal trend 0001.
Similarity of OTU richness between PPI use and CDI
Using subject data rarefied to 75,000 reads/sample, ob-
served OTU diversity was compared between the five
CDI subjects as well as the time points of male or female
subjects (Additional file 2: Table S3). The change in observed
OTUs in CDI subjects and all healthy subjects were also
compared by time interval (Table 1). We reported marked
differences in observed OTU counts between healthy sub-
jects at baseline and those with CDI that erode after 1 week
and 1 month of PPI therapy (Table 1). This difference in
observed OTU counts is also apparent when the healthy
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(Additional file 2: Table S3).
No compositional overlap between PPI use and CDI
Non-metric multidimensional scaling (NMDS) and Sour-
ceTracker were used to determine if healthy subjects using
a PPI retained microbial ecological similarity to baseline
samples or if a CDI-like microbial composition could
be detected. Compositional similarity to the CDI pa-
tients was potentially indicated in one of the subjects
(D02d, Figure 2). The NMDS plots showed strong over-
lap of on-PPI time points (Figure 2). A SourceTracker
calculation indicated the closest sink to on-PPI or after-
PPI samples was baseline compared to the five CDI sub-
jects, and an “Unknown” group as visualized in a ternary
plot (Additional file 2: Figure S5).
No detectable PPI-induced pathway changes
The nearest sequenced taxon index (NSTI), a metric to
determine divergence of taxonomic reads from closed ref-
erences, was calculated per sample with mean ± standard
deviation of 0.07 ± 0.03. These reported values are within
the range of the NSTI generated from the phylogenetic
investigation of communities by reconstruction of unob-
served states (PICRUSt) benchmarking of mammalian gut
samples (0.14 ± 0.06) [28]. No significant change in en-
richment in any of the Kyoto Encyclopedia of Genes andFigure 2 No overlap of on-PPI and CDI subjects. NMDS plots show no
subjects with C. difficile infection, with strong overlap between all subjectsGenomes (KEGG) pathways was detected during PPI
treatment of healthy subjects. However, there was a sig-
nificant enrichment in glycine-serine-threonine metabol-
ism in healthy patients pre-PPI use compared to the CDI
subjects (p ≈ 0.001, Figure 3, Additional file 2: Table S4).
The enrichment of this pathway decreased during the
course of PPI treatment until it was not significantly
different from the CDI group, and the enrichment of
this pathway increased during recovery until signifi-
cantly it was different from the CDI subjects (p ≈ 0.007,
Figure 3, Additional file 2: Table S4).
Individual ecological distinctiveness is preserved
The unweighted UniFrac β-diversity distance matrix was
calculated from a sample rarefied to 75,000 reads/sample
(Figure 4), with one subject samples remaining most simi-
lar to each other for the duration of treatment (subjects 4).
Three subjects had their 1-month sample as the outlier
(subjects 6, 8). Four CDI subjects (C. difficile (CD) subjects
1, 2, 4) clustered closely to each other, with CDI subject 3
forming a sub-cluster with healthy subject 1’s post-treatment
sample (D01d) and CDI subject 5 clustering with subject 3
at baseline (D03a).
Discussion
We conducted a study that longitudinally tracked the fecal
microbiome of healthy humans before, during, andtaxonomic overlap between short- and long-term PPI users and













Figure 3 KEGG Pathway disruptions on PPI. Plot depicts relative enrichment of KEGG pathway “Glycine, Serine, Threonine Metabolism” at start
of treatment, one week into treatment, and at the end of the one-month program. The difference in relative abundance of the pathway for the
duration of treatment did not vary significantly, with significant difference in means between subjects with C. difficile and other time points except the
one-month group (§ p <0.05; §§ p <0.005).
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the hypothesis that PPI use can cause perturbations to the
healthy gut microbiome that bear similarity to the micro-
bial changes that occur in CDI. While limited by a small
sample size, we observed that PPIs induce a marked and
persistent decrease in observed OTU count, a surrogate
for microbial diversity. At the end of the 28-day treatment
period, the observed OTU counts were similar to those
from patients with a first CDI episode indicating the
potential for PPIs to negatively influence the robustness of
the host microbial ecology and increase the susceptibility
to CDI.
This is the first study to examine the impact of PPI use
on the human gut microbiota using high-throughput
sequencing. Our findings are consistent with past longi-
tudinal studies of the GI microbiome that indicate
stable individual microbial communities [29]. That is to
say, despite the effects of PPI use, samples from the
same subject taken over time remained more similar to
each other than to the samples obtained from the other
healthy subjects. In our work, this is supported by the un-
weighted UniFrac β-diversity distance matrix (Figure 4)
showing clusters comprised of individual samples. NMDS
plots also show minimal movement of individual samples
over time, despite the overall reduction in diversity over
time with PPI use.Garcia-Mazcorro et al. showed that PPI usage in canines
resulted in an increase of Lactobacillus spp. in male (n =4)
and female dogs (n =4) and a decrease in Faecalibacter-
ium spp. and Bacteroides-Prevotella-Porphyromonas in
the male dogs only [30]. In contrast, our comparison of
taxa highlighted in Garcia-Mazcorro et al. revealed no
significant differences during PPI treatment (Additional
file 2: Table S5). The lack of taxa-specific associations in
our human cohort may be due to the larger baseline dif-
ferences that arise due to differences in age, environment,
diet, and starting microbiomes, effects that are more diffi-
cult to overcome with small sample sizes. This variability
can be observed in changes of relative abundance of taxa
over time that varies between subjects (Additional file 2:
Figure S6). Garcia-Mazcorro et al. also collected muco-
sal biopsy samples from the stomach and duodenum of
the dogs, reporting a decrease in Helicobacter spp. and
a corresponding increase in the relative abundance of
other bacteria in the stomach. However, in the duode-
num, an overall increase in the abundance of all bacteria
(i.e., small bowel bacterial overgrowth) was seen.
Garcia-Mazcorro et al. did not report major qualitative
changes in the phylogenetic composition of stomach
and duodenal microbial communities after PPI use. A
limitation of our study is that, given the complexities
and expense of obtaining specimens from the upper GI
Figure 4 Beta diversity of samples. Beta diversity via unweighted UniFrac of samples from healthy volunteers and C. difficile patients was
calculated for all samples against all samples to generate a distance matrix. Samples were then clustered by Euclidean distance. CDI patients (4/5)
formed a cluster distinct from the healthy volunteers and cluster by patient more than time point.
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area of particular interest given the proximity to the
acid-producing stomach. Further study in this area is
needed.
Kanno et al. administered omeprazole to mice and
found dose-dependent changes in fecal microbial commu-
nities [26]. In contrast to the study of Garcia-Mazcorro,
they found a higher abundance of all groups of fecal bac-
teria with the exception of Bifidobacterium during omep-
razole use. Because it is unlikely that omeprazole reachesthe colon intact, it was speculated that the microbial
changes observed in the feces relate to an increase in bac-
terial load entering the colon or to changes in dietary pro-
tein reaching the colon given the role of gastric acid in the
early stage of protein digestion.
Direct effects of PPIs on gut microbes may provide an
explanation for the observed changes to community struc-
ture and species diversity during treatment, and may also
provide a potential mechanism whereby PPIs increase the
risk of CDI. Bacterial counts of many species increase in
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zole can inhibit the growth of many gut microbial species
[31]. Loss of microbial diversity is a consistent feature in
CDI patients [32] and animal models of antibiotic-mediated
CDI [33]. In vivo antibiotic treatment leads to an increase
in gut sialic acid, a favored catabolite of C. difficile whose
availability is strongly associated with C. difficile bacterial
load [34]. The published literature provides strong evidence
for the role of nutrient competition between the gut micro-
biome and C. difficile in utilization of available amino acids
[35], monomeric glucose, N-acetylglucosamine, and sialic
acids [36]. Although disruption of a healthy gut micro-
biome can create an environment conducive to C. difficile
proliferation, the specific changes in host and microbial fac-
tors that directly lead to C. difficile invasion in humans re-
main unclear.
In addition to eliminating nutrient competitors, PPI
use may directly affect gene expression across meta-
bolic pathways in favor of C. difficile growth. We de-
tected a significant decrease in enrichment of the KEGG
pathway “glycine-serine-threonine metabolism” in CDI sub-
jects compared to the healthy subjects. This pathway com-
bines the synthesis of threonine and serine from separate
pathways and the final production of glycine from either
amino acid [37]. Glycine is a well-known enhancer of C.
difficile spore germination [38]. Glycine and threonine sup-
plementation has been shown to increase in vitro bacterial
load and together lead to markedly increased C. difficile
toxin production [39]. Given these effects, the reduction of
enrichment of glycine-serine-threonine in CDI is unex-
pected, and future work may attempt to directly quantitate
amino acid concentrations in the gut in CDI subjects and
GI-healthy subjects. The lack of significant changes in
enrichment of this pathway in healthy subjects is expected
given the lack of adverse effects reported by the healthy
subjects. Further study is warranted to investigate the
premise that PPI use can alter production of metabolites
that serve as C. difficile germinants, growth factors, and
toxin production enhancers.
Specific bile salts and glycine act as co-germinants
of C. difficile spores, converting them to vegetative
(infectious) forms. In vivo and independent of C. diffi-
cile, glycine appears to alter the ratio of deconjugated
(primary bile salts) to conjugated (secondary bile salts)
in the intestine [22]. In contrast, secondary bile salts
such as deoxycholate prevent vegetative growth
[38,40]. After severe disruption of gut microbial popula-
tions by PPI-induced hypochlorhydria, secondary bile salts
are significantly reduced, allowing unrestricted vegetative
growth [41]. Chenodeoxycholate, a primary bile salt, in-
hibits germination and protects the small intestine by
inhibiting production of vegetative forms, until spores
reach the anaerobic environment of the large bowel
[42]. These conditions are reversed by cholestyramine,which binds bile salts that stimulate spore germination
[43].
The direct effect of PPIs on C. difficile can be divided into
effects on spore germination, effects on growth, and effects
on toxin production. A recent report found that C. difficile
spore germination in gastric contents was increased by
nutrient supplementation as opposed to PPI use but did
not compare germination efficacy with and without PPI
[44]. No research is currently available to describe the effect
of PPI on C. difficile spore germination or vegetative
growth, but PPIs have a notable effect on toxin production
of vegetative C. difficile. In vitro, some strains of C. difficile
possess enhanced toxin production in the presence of
omeprazole, independent of final pH [45]. Strain-level vari-
ations in enhanced toxin production of omeprazole are
likely to be an explanation of why PPI use is not as strongly
associated with CDI as other well-known risk factors.
Conclusions
In conclusion, we have shown that PPI use in humans re-
duces microbial diversity, a condition found in subjects
with CDI. A follow-up study with a greater number of re-
cruited subjects will improve our confidence in this finding,
a necessary precursor to future studies. Further investiga-
tion into the role of PPIs in altering metabolism in gut bac-
teria is likely to solidify our understanding of PPI-mediated
changes within the gut microbiome and provide additional
insight into the association between prolonged PPI usage
and CDI acquisition. Finally, additional research should be
performed in an effort to mitigate the loss of microbial
diversity consequent to PPI use.
Methods
Ethics statement
The study was approved by the Mayo Clinic Institutional
Review Board (#13-000180) and registered on ClinicalTrials.
gov (NCT01822977). Written informed consent was provided
by all individuals enrolled.
Study participants
Study participants were recruited at Mayo Clinic in Arizona.
Ten volunteers without acute or chronic GI symptoms or
conditions and five adult patients experiencing their first epi-
sode of CDI were enrolled. Healthy subjects were screened
for current or chronic GI symptoms using a 16-item ques-
tionnaire. Only those with an absence of symptoms were
eligible to participate. Exclusion criteria for healthy volun-
teers included prior surgery altering the esophagus, stomach,
and intestine; chronic daily use of medications affecting GI
secretion or motor function; the presence of any GI-motility
affecting systemic diseases or untreated psychiatric disease;
and pregnancy. Use of the following medications was pro-
hibited: antibiotics within 2 months of the start of the study,
probiotics within 2 weeks, and chronic use of medications
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or motility (prokinetic agents, narcotic analgesics, laxatives,
anticholinergics, antidiarrheals). Those on a stable dose of
daily fiber were allowed to participate. In the C. difficile
group, only patients experiencing their first episode of CDI
who had not yet been treated were eligible to participate.
Study design
Following consent, a fresh stool sample was collected from
the ten healthy subjects (T0). These ten subjects were then
randomly assigned to receive omeprazole 20 mg once daily
(n =5) or twice daily (n =5) for 28 days. Stool samples were
collected after 7 (T7) and 28 (T28) days of omeprazole use.
A final stool sample was collected 1 month after discon-
tinuation of omeprazole (T56). Additionally, fresh stool
samples were collected from five treatment-naïve CDI
subjects before commencing treatment.
Sample collection and storage
Subject stool samples were passed into a stool collection
device at the subject’s home in the morning, with the sub-
ject transferring a portion into a specimen container. The
specimen container was brought to the Mayo Clinic in
Arizona study coordinator fresh within 6 hours of passing.
C. difficile samples were taken from consented patients
clinical specimens after C. difficile testing was completed.
At the Mayo Clinic in Arizona, the specimen was frozen
at −80°C before being shipped to the Mayo Clinic in
Rochester in an insulated container with dry ice. At the
Mayo Clinic in Rochester, samples were stored at −80°C
until DNA extraction.
DNA extraction and library preparation
DNA was extracted from samples using the MoBio
PowerSoil Kit (MoBio Laboratories, Carlsbad, CA, USA).
Genomic DNA (gDNA; 50 ng) was used as template for a
polymerase chain reaction (PCR) with 0.3 uM V3-V5 bar-





the bacterial 16S gene, along with Kapa HiFi Hotstart
Ready Mix (Kapa Biosystem). PCR conditions were
set to 95°C/3 min, 35 cycles of 98°C/30 s, 70°C/15 s,
72°C/15 s, and finally 72°C/5 min in a Bio-Rad T100
Thermal Cycler. PCR product sizes were verified using
Agilent Tapestation with reaction cleanup and DNA was
purified using an epMotion automated system (Eppendorf)
with Agencourt AMPure PCR Purification System. Final
quantitation was performed using QuBit HS dsDNA kit
using the QuBit 2.0 flurometer (Life Technologies). Samples
were pooled to equal concentrations and sequenced on one
lane of MiSeq at the Mayo Genomics Facility using MiSeqReagent Kit v2 (2 × 250 reads, 500-cycles) (Illumina Inc.,
San Diego, CA).
NGS data analysis
Quality control of 16S reads can strongly effect ecological
diversity metrics such as alpha- and beta-diversity, with
filtering of low quality reads playing an important role in
reducing the count of spurious OTU detection [47].
Briefly, after quality-filtering using Trimmomatic, paired
16S reads were de-replicated and singletons and chimeras
were removed and clustered by similarity with representative
sequence selection with USEARCH, part of the UPARSE
package [48]. Benchmarks by the author of the UPARSE
package against mock OTU sets suggest that UPARSE better
approximates actual species diversity due to its conservative
nature. Representative sequences representing the OTUs
were classified using Greengenes [49] 13_5 database with
mothur 1.32.1 [50]. Clean sequences were re-mapped to the
representative OTUs using USEARCH. Output files were
converted to BIOM format and processed using QIIME
1.7.0 [51]. An observed species rarefaction curve was gener-
ated to measure saturation of sequencing (Additional file 2:
Figure S1).
As the default Greengenes database did not possess C.
difficile representatives, 72 sequences and appropriate tax-
onomy were downloaded from SILVA SSU r117 [52] by
searching the online version of r117 for “clostridium diffi-
cile” for non-repetitive reference sequences (Ref(NR)).
The sequences and taxonomic data were concatenated to
the reference fasta and taxonomy files, respectively. This
supplemented Greengenes99 file was then used to re-classify
the OTU representative reads from USEARCH in mothur
using the classify.seqs function.
The R function sample was used to perform random
sampling with replacement. The input used was a vector of
incrementing values from 1 to a number equal to the total
number of OTUs in the community matrix. For each sam-
ple, the probability of selecting any OTU was weighted by
the relative abundance of that OTU in a particular sample.
OTUs were then randomly selected 75,000 times for each
sample, a value less than the read-count of the sample with
the lowest read-count (75,506). The list of randomly sam-
pled OTUs per subject was converted into a down-sampled
community matrix by taking the randomly sampled OTU
counts and incrementing the rows of a blank community
matrix corresponding to the randomly selected OTUs.
Comparison of healthy and CDI datasets
SourceTracker estimates the proportion of a sampled mi-
crobial community that is derived from defined source
communities. Previous uses include estimating the propor-
tion of the microbiota detected at a variety of “sinks” from
various environmental “sources” [53]. SourceTracker 0.95
from Quantitative Insights Into Microbial Ecology (QIIME)
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of various sink samples (T7, T28, T56) to sources (T0,
CD). The mapping file previously used with QIIME was
appended to include the additional columns required to
designate sources and sinks. The healthy subjects and CDI
subjects at baseline were used as sources, with healthy
subjects at 7-days, 28-days, and 1-month post-treatment
treated as sinks. SourceTracker performed rarefaction of
75,000 reads with ten restarts and 100 burn-in iterations.
The percent relationship between the aggregate sinks and
the aggregate CDI and T0 sources were plotted on a
ternary plot constructed using the R package vcd.
NMDS was selected to analyze the between-sample
distances of the community matrix [54]. NMDS uses
rank-order of pairwise distances in a distance matrix and
is a more robust technique for measuring relatedness of
samples [55]. NMDS analysis was used to determine vari-
ation between CDI- and PPI-consuming subjects over time
using a community matrix rarefied to 75,000 reads/sample.
The R package vegan was used for NMDS calculations;
specifically, function metaMDS was used to perform the
NMDS calculation, followed by shape generation with ordi-
hull and labeling of samples via orditorp. Shapes were gen-
erated based on sample group and time point, comprising
CDI subjects, healthy subjects at baseline (T0), subjects
after 1 week of PPI treatment (T7), 1 month of treatment
(T28), and 1 month after ceasing PPI treatment (T56).
Diversity measures
Taking biom and tree files generated from UPARSE and
mothur, data were converted to tabular form and analyzed
using R-3.1.0 on R-Studio 0.98. Observed species counts
were calculated using function “specnumber” from package
vegan. Shannon diversity was calculated using function
“diversity” with index = “shannon” from package vegan.
The rarefaction depth utilized for subsequent statistical
analyses was 75,000 reads/sample. Chao diversity was cal-
culated using function specpool with index = “chao” from
package vegan. After rarefaction in QIIME, unweighted
UniFrac β-diversity was calculated via beta_diversity.py in
QIIME. The distance matrix was exported to R and visual-
ized using heatmap, using Euclidean distance to cluster
rows and columns.
Statistical testing
To test for normality of the data, the skewness function
from R library e1071 [56] was used to evaluate the distri-
bution of observed OTU data. Non-parametric Wilcoxon
tests were chosen to evaluate statistical significance of
observed differences between datasets. Between healthy
subjects longitudinally paired data, one-tailed Wilcoxon
signed rank was used to evaluate if observed OTU diver-
sity decreased during PPI use and was still lower than at
baseline. The Wilcoxon rank sum test with continuitycorrection was used to compare non-matched CDI sub-
jects and healthy subjects at various time points. Wilcoxon
rank sum was also used to compare high and low dosage
groups and observed OTU counts between men and
women.
Synthetic metagenome prediction
PICRUSt was used to infer metagenomes from the 16S
data [28]. From the 16S data we extrapolated gene content
based on the evolutionary distance of a detected OTU to
the closest relative with a completed reference genome.
Very close evolutionary relationships to an organism with
a closed reference genome would improve the confidence
of predicted genome content, in contrast to OTUs with a
closed reference genome only available from a distant
evolutionary relative. The distances of all taxa to the near-
est organism with closed reference genome were summed
to derive the NSTI for each sample. OTU picking was re-
performed in QIIME using pick_closed_reference_otus.py.
The resulting biom file was then normalized using nor-
malize_otus.py to convert the OTU content into KEGG
gene content. Pathway annotation was generated using
predict_metagenomes.py with the normalized biom file as
input with default output using KEGG pathway informa-
tion [37]. KEGG pathway data was then exported in tabu-
lar form to R-3.1.0 in R-Studio 0.98 for subsequent
analysis.
Longitudinal changes
Evaluation of longitudinal trends was performed by
transforming numeric counts per OTU into presence/
absence (1/0) for each subject’s four time points (base-
line, short-term PPI, long-term PPI, post-PPI recovery).
Absence (“0”) was strictly defined as no reads detected,
with presence (“1”) defined as detectable reads per OTU
for a given subject. For two outcomes and four time
points, this resulted in 24 − 1 combinations of an OTU
after subtracting the combination corresponding to the
absence in all time points (0000). From a rarefied com-
munity matrix of 75,000 reads per sample, the behavior
of each OTU in each subject was classified into 1 of 15
bins corresponding to combinations of presence and ab-
sence at each time point (0001, 0010, 0100, 1000, 1111,
etc.). The number of OTUs that were classified as be-
longing to each bin were calculated and plotted to assess
the effects of PPI usage on multiple species per person.
Separately, longitudinal changes to relative abundance
after commencement of treatment were calculated by
taking the log10 transform of relative abundance per
taxa at each post-treatment time point for each individ-
ual and dividing by the relative abundance of that taxa
at baseline. For transforms that equaled infinity, the
value was fixed at +10. For transforms equaling negative
infinity, the value was fixed at −10.
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Figures include per-sample observed OTU rarefaction plots (Figure S1),
rarefaction sensitivity plots (Figure S2), PPI effects on gender (Figure S3),
and dosage (Figure S4). SourceTracker ternary plot describes relationship of
on-PPI samples to CDI and baseline (Figure S5). Differential change at
family level over time per subject presented on heatmap (Figure S6).
Time-longitudinal plots for Shannon (Figure S7) and Chao
(Figure S8) diversity relative to CDI. Tables include statistics for
rarefaction sensitivity analysis (Table S1) and longitudinal OTU bins
per subject (Table S2). Table of statistical tests for gender effects of
PPI (Table S3), KEGG pathway enrichment (Table S4), changes in
enrichment for Garcia-Mazcorro taxa (Table S5) and longitudinal
changes to Chao and Shannon diversity (Table S6).
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